Bogen, Jan Patrick ; Grzeschik, Julius ; Jakobsen, Jørn ; Bähre, Alexandra ; Hock, Björn ; Kolmar, Harald (2021):
Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics. (Publisher's Version)
In: Frontiers in Oncology, 11, Frontiers, e-ISSN 2234-943X,
DOI: 10.26083/tuprints-00019435,
[Article]
|
Text
fonc-11-672262.pdf Available under: CC BY 4.0 International - Creative Commons, Attribution. Download (3MB) | Preview |
Item Type: | Article |
---|---|
Origin: | Secondary publication via sponsored Golden Open Access |
Status: | Publisher's Version |
Title: | Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics |
Language: | English |
Abstract: | Bladder cancer is a frequent malignancy and has a clinical need for new therapeutic approaches. Antibody and protein technologies came a long way in recent years and new engineering approaches were applied to generate innovative therapeutic entities with novel mechanisms of action. Furthermore, mRNA-based pharmaceuticals recently reached the market and CAR-T cells and viral-based gene therapy remain a major focus of biomedical research. This review focuses on the engineering of biologics, particularly therapeutic antibodies and their application in preclinical development and clinical trials, as well as approved monoclonal antibodies for the treatment of bladder cancer. Besides, newly emerging entities in the realm of bladder cancer like mRNA, gene therapy or cell-based therapeutics are discussed and evaluated. As many discussed molecules exhibit unique mechanisms of action based on innovative protein engineering, they reflect the next generation of cancer drugs. This review will shed light on the engineering strategies applied to develop these next generation treatments and provides deeper insights into their preclinical profiles, clinical stages, and ongoing trials. Furthermore, the distribution and expression of the targeted antigens and the intended mechanisms of action are elucidated. |
Journal or Publication Title: | Frontiers in Oncology |
Journal volume: | 11 |
Publisher: | Frontiers |
Collation: | 25 Seiten |
Classification DDC: | 500 Naturwissenschaften und Mathematik > 540 Chemie 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin, Gesundheit |
Divisions: | 07 Department of Chemistry > Fachgebiet Biochemie |
Date Deposited: | 03 Sep 2021 12:31 |
Last Modified: | 03 Sep 2021 12:31 |
DOI: | 10.26083/tuprints-00019435 |
Corresponding Links: | |
URN: | urn:nbn:de:tuda-tuprints-194359 |
Additional Information: | Keywords: antibody engineering, protein engineering, bladder cancer, urothelial carcinoma, ADC, immunotherapy, immuno-oncology, recombinant viral vector vaccines |
URI: | https://tuprints.ulb.tu-darmstadt.de/id/eprint/19435 |
Export: |
![]() |
View Item |